Symbol | Exchange | Currency |
|---|
RBC Capital analyst Brian Abrahams maintained a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) on Thursday, setting a price target of $133, which is approximately 88.55% above...
-- Application website is now open for the 2021 Scholarship Program ---- The Company will award up to 15 academic scholarships to individuals diagnosed with Duchenne muscular...
Investors often rely on the healthcare sector to safeguard their investments. This is because demand for healthcare services does not vary much with market conditions. Also,...
Gone are the days when investors used to be happy with just earnings growth. Now, earnings improvement (no matter how big it is) seems inadequate for solid moves in the market. It...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Sell | Sell | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 322.75 | 349.20 | 317.27 | -5.53 | -1.68% | 39.78M | NASDAQ | |||
| 239.09 | 240.95 | 238.13 | -0.14 | -0.06% | 11.29M | NYSE | |||
| 118.35 | 122.00 | 116.56 | -2.49 | -2.06% | 18.71M | NYSE | |||
| 60.74 | 61.09 | 59.55 | +1.51 | +2.55% | 17.50M | NYSE | |||
| 5.85 | 5.87 | 5.83 | +0.06 | +1.04% | 252.75K | NYSE | |||
| 2.78 | 3.01 | 2.72 | -0.17 | -5.76% | 216.67K | NASDAQ | |||
| 2.87 | 3.34 | 2.67 | -0.470 | -14.07% | 1.18M | NASDAQ | |||
| 23.06 | 25.46 | 22.62 | -3.62 | -13.57% | 33.36M | NYSE | |||
| 23.15 | 24.06 | 22.69 | -0.55 | -2.32% | 58.85M | NYSE | |||
| 2.78 | 3.045 | 2.78 | -0.2300 | -7.64% | 408.15K | NASDAQ | |||
| 12.57 | 13.65 | 12.23 | -0.60 | -4.56% | 2.93M | NYSE | |||
| 156.44 | 166.25 | 152.80 | -10.09 | -6.06% | 7.86M | NYSE | |||
| 26.09 | 28.77 | 24.61 | -2.30 | -8.10% | 69.17M | NASDAQ | |||
| 3.69 | 3.97 | 3.66 | -0.11 | -2.89% | 111.19K | NASDAQ | |||
| 77.17 | 79.65 | 75.76 | -1.40 | -1.78% | 1.86M | NASDAQ |
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.